Status:
UNKNOWN
Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy
Lead Sponsor:
Hunan Cancer Hospital
Collaborating Sponsors:
The Third Xiangya Hospital of Central South University
Conditions:
Nutrition Aspect of Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as research objects to conduct nutritional risk screening, malnutrition assessment and quality of life assessme...
Detailed Description
In view of the high incidence of malnutrition in esophageal cancer and gastric cancer and chemotherapy may further aggravate malnutrition and reduce quality of life. According to the inclusion criteri...
Eligibility Criteria
Inclusion
- Esophageal or gastric cancer confirmed by histology or cytology;
- Age 18-75 years old, gender unlimited;
- Blood routine: hemoglobin ≥90g/L, absolute neutrophil count (ANC) ≥1.5×109/L, platelets ≥100×109/L; (2) Liver and kidney function: alanine transaminase（ALT）, glutamic-oxalacetic transaminease（AST）≤2.5 times the normal upper limit (with liver metastasis ≤5 times the normal upper limit); ALP≤2.5 times the normal upper limit (≤5 times the normal upper limit for patients with liver or bone metastasis); Serum total bilirubin (TBIL) was less than 1.5 times the normal upper limit. Serum creatinine (SCr) \< 1.5 times the upper limit of normal; ③ Blood biochemistry: Serum albumin (ALB) ≥30g/L;
- Predicted survival of more than 3 months; It is planned to continue chemotherapy for \>3 cycles in the hospital or outpatient department
- All patients participated in this study voluntarily and signed informed consent.
Exclusion
- Other tumors, including pancreatic cancer, liver cancer and other solid digestive tract tumors, colon cancer, rectal cancer and other tubular lower digestive tract tumors;
- Have serious heart, lung and brain diseases; Complicated with chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency, etc.
- Fever associated with infection; Have difficult-to-control diabetes or other metabolic diseases;
- Patients with unstable vital signs and multiple organ failure;
- The patient has poor cognitive ability and is unable to answer questions or fill out questionnaires.
- The investigator believes that the subjects have a history of other serious systemic diseases or are not suitable for participating in this clinical study for other reasons
Key Trial Info
Start Date :
August 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06022770
Start Date
August 30 2023
End Date
December 30 2024
Last Update
September 5 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.